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Chapter 12 Outcome measures and case definition
1. Introduction to outcome measures and case definition
Field trials of health interventions are designed to assess the impact of one or more interventions on the incidence,
duration, or severity of specified diseases, or on intermediate variables or risk factors considered to be closely related
to these measures of disease (for example, hygiene behaviours for diarrhoeal diseases, reduction in density of parasite
vector, reduction of indoor air pollutants for pneumonia, or reduction of salt intake for hypertension). The measures
chosen to assess the impact of the interventions are called the outcome measures in the trial (or the trial endpoints).
Such measures should be defined at the time the trial is designed and should be specified in detail in the study
protocol. The outcomes should be compared between those in the different intervention groups and should be
measured in a consistent way during the course of the trial in the different groups. Clear definitions are also necessary,
so that the measures can be replicated in other trials and meaningful comparisons made between trials. Failure to pay
sufficient attention to the precise definition of the primary outcome measures at the start of a trial may lead to
confusion in interpreting the results or can even invalidate them.
As discussed in Chapter 4, Section 5, several different outcome measures may be employed in a trial. It is important
to decide which is of most interest (primary outcome), as this has major design implications, particularly in terms of
the study size and duration. Trials may have other outcomes (secondary or tertiary) that may be important to measure,
although they will generally not determine the size of the trial. In Table 12.1, there are some examples of primary and
secondary outcomes for trials of different interventions.
In this chapter, different types of outcome measures are reviewed in Section 2, and factors influencing the selection of
these are discussed in Section 3. The importance of standardizing measurements between different observers is
stressed in Section 4.1, and there is a discussion of how the results of a trial may be influenced by poor sensitivity or
specificity in the outcome measures in Section 4.2. Finally, ways of avoiding bias and maintaining quality control
(QC) in case ascertainment methods are reviewed in Sections 4.3 and Sections 4.5.
2. Types of outcome measures
2.1. Primary, secondary, tertiary
2.1.1. Primary outcomes
Primary outcomes are the most important outcomes of the study, the ones that determine its design and the study size.
They represent the main reason the trial is being conducted. Normally, a trial has only one primary outcome, so, for
each main question in the development of a new drug, vaccine, or intervention, one specific trial is usually conducted.
However, more than one primary outcome may be selected in some trials, provided the design and sample size allow
it and if measuring them in the study does not substantially add to the cost or complicate the design or conduct of the
trial. For example, Phase I or II clinical trials usually have several primary outcomes (such as the safety of a new drug
or vaccine, evaluated through a series of clinical outcomes, as well as the immunogenicity of the vaccine or
pharmacodynamics of the drug). Phase III or IV trials have fewer primary outcomes, and often only one. Primary
outcomes need careful definition prior to the start of the trial (indicator, instrument to be used, measurement to be
taken, values which will be considered as a positive or negative result, which laboratory will be used, etc.); these
should be agreed upon among investigators, sponsors, and any regulatory agencies overseeing the trial.
2.1.2. Secondary and tertiary outcomes
Trials often have additional important outcomes, but these are not usually used to determine the trial design and
sample size. They are included as secondary or tertiary outcomes to be measured in the trial. These outcomes may not
be statistically conclusive, since the trial may not have been designed with the power to evaluate them, but they can
be very useful to generate further hypotheses and guide future trials. Because of their importance in justifying future
studies, these additional outcomes also need careful definition and measurement and should be fully specified in the
protocol, since extra resources often are needed to measure and evaluate them.
22-4-2020 Outcome measures and case definition - Field Trials of Health Interventions - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK305519/?report=printable 2/14
2.1.3. Other variables which are not study outcomes
Often, trials have other variables measured in the study not directly related to the study outcomes. Variables, such as
age, gender, educational or socio-economic level, and nutritional status, may be used to evaluate potential effect
modifiers or confounders to the study outcomes. These variables also need to be defined and considered at the
beginning of the study, so they may be included in any pilot investigations.
2.2. Clinical case definitions
2.2.1. Physician-based case definitions
In some trials, outcomes are based on a clinical diagnosis by a physician, without any type of laboratory confirmation.
For example, pneumonia may be diagnosed by auscultation in a trial evaluating the impact of an intervention designed
to reduce indoor air pollution. This type of outcome is subjective, and interpretation may vary among doctors, and
even among experienced specialists. Nevertheless, in many clinical trials, physician-based clinical diagnosis
determines the main outcome of the study, since no alternatives exist. For many diseases, standardized criteria for
defining a ‘case’ have been established by experts. The International Classification of Diseases (World Health
Organization, 2010; see also <http://www.who.int/classifications/icd/en>), which is revised about every 10 years,
provides a basis for coding all diseases in a systematic way and is widely used for clinical and epidemiological
research.
If standardized criteria for a ‘case definition’ have not been developed for the disease under study, a suitable
definition should be established before the trial starts. For infectious diseases, there is often the need to distinguish
between infection and disease, since clinical manifestations of infections may vary widely, from subclinical to
overwhelming disease. For many trials, the main outcome of public health interest may be those infections that are
severe or fatal. Careful definitions of these types of clinical categories are important, and, if available, the criteria
used in other studies should be used to facilitate comparability across studies. The physicians charged with making
diagnoses in the trial should discuss and agree the criteria they will be using to make a diagnosis and should compare
their diagnoses on a range of patients prior to the start of the trial and at periodic intervals throughout the trial (see
Section 2.2.5). Cases may also be classified as suspected, probable, or definite, using clinical and/or laboratory
criteria.
In some populations, the conduct of a clinical examination may be problematic. Physical examinations are virtually
always highly personal and may raise sensitive issues concerning individual dignity. In those populations when
privacy is required, a third person in the examination room is often important, both to reassure the patient and to
provide protection against possible charges of misconduct. In the case of children, the mother’s presence should
normally be requested; for the examination of women, a nurse and an appropriate family member may be needed,
even when the examiner is a woman. If there are local codes of behaviour that cover such circumstances, these must
be adhered to.
2.2.2. Laboratory-based case definitions, including any diagnostic procedure
Commonly, a clinically defined study outcome involves the combination of a clinical assessment with the support of a
confirmatory laboratory, or other diagnostic, procedure. For example, the clinical diagnosis of malaria may be
supported by a positive identification of the parasite in the blood, or the diagnosis of dengue fever in a subject with 48
hours of elevated temperature with a positive immunoglobulin M or viral antigen present in the blood, as detected by
polymerase chain reaction, or the clinical diagnosis of pneumonia with a confirmatory chest X-ray. All these
diagnostic procedures need careful definition, including the technique, machine, or equipment to be used, reference
values considered normal for the study population, and the level at which they will be considered abnormal. It is
important to describe, in the protocol, how the test or procedure will be conducted and whether a reference laboratory
will be used to validate the site laboratory or procedure—also, how procedures used by laboratory personnel to
interpret results will be standardized and how monitoring for QC will be done. Some diagnostic results are also
affected by subjectivity such as reading the results of a chest X-ray. In such cases, protocols have been developed to
try to standardize the diagnosis, such as establishing defined criteria for each type of pathology in advance, having
two independent, blinded radiologists read all X-ray films, with a third radiologist reading all films where there were
disagreements, with their result used as the tiebreaker. Similar procedures have been developed to read blood smears
for malaria. All these options have important consequences on the trial logistics and cost, so careful consideration
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needs to be given to them when designing the trial and selecting its study outcomes. Issues concerning laboratory tests
of relevance to diagnosis in field trials are outlined in Chapter 17.
2.2.3. Lay worker-based case definitions
Some trials use lay workers (fieldworkers) to measure a study outcome. Examples of such trials are diarrhoeal
diseases where prevalent diarrhoea might be defined as three or more liquid or semi-liquid stools passed in a 24-hour
period, as reported by the mother or the child’s caretaker to a fieldworker, or hygiene behaviours observed by
fieldworkers in spot household checks during a hand-washing intervention trial. These types of outcomes are usually
captured in questionnaires or study forms. Interviewing techniques and questionnaire design are discussed in Chapter
14.
Fieldworkers may also measure a clinical indicator such as the body temperature or respiratory rate. Because of the
high cost of using physicians, in many trials, lay workers or paramedical workers are trained to assess clinical signs
and symptoms. When using lay workers or professional fieldworkers, such as nutritionists, auxiliary nurses, or nurse
technicians, it is essential to train them and standardize the methods they use, in order to assure uniform
implementation of these procedures in the field throughout the study, with good supervision and QC procedures.
2.2.4. Case definitions using secondary data sources
In some trials, such as in phase IV trials, existing surveillance systems may be used to define a study outcome. These
secondary data sources, in which trial outcomes are not measured directly by study staff, will have the limitations
intrinsic to the quality of the existing surveillance system. Examples of such study outcomes are post-marketing
passive surveillance of vaccine or drug-related SAEs, such as hospitalizations of any type, after the introduction of the
intervention into general use. They could also be used to evaluate the efficacy of a new vaccine or intervention on an
important outcome which, for reasons of cost or ethics, could not be measured in a phase III trial such as the impact of
a new vaccine on mortality.
2.2.5. Standardization
All study outcomes to be used in a clinical trial need to be properly standardized. When an outcome requires
physicians, other professionals, or lay workers to measure it, standardization usually requires predefined exercises,
with the use of an expert to act as the ‘standard’ against which the group is compared, defining differences which will
be considered acceptable as part of the precision of the study. These standardization exercises could be done with real
patients or mock subjects who may be trained actors. The use of videos showing different types of patients, which all
participants evaluate independently, is a very useful exercise to help standardize them against the ‘standard’ observer.
Standardization of this sort is not easy; it requires resources, time, and, in many cases, patients or volunteers willing to
be examined by multiple persons. Ideally, the same set of samples, films, blood smears, subjects, or videos would be
evaluated again by the same individual in a random order, under code, to allow the calculation of intra-observer
reproducibility. All these procedures need to be carefully described in operating manuals and recorded, so they can be
reviewed by investigators, collaborators, or regulatory agencies. In studies that last for several years, it is important to
re-standardize observers every 6 to 12 months or if any observer needs to be replaced, to assure that the quality of the
study is maintained.
2.2.6. Inclusion and exclusion criteria
An important component of an outcome definition is the description of the inclusion and exclusion criteria for the
subjects to be evaluated in the trial. Ideally, the trial results should be able to be generalized to the whole population in
which the intervention will be used. Under ideal circumstances, nobody should be excluded from the trial. However,
for ethical, logistic, or analytical reasons, most trials establish stringent inclusion and exclusion criteria to exclude
certain persons from participation. These criteria could be established on the basis of factors such as age, gender,
literacy, being healthy or not, not affected by chronic diseases different from the study outcome, or not affected by
other conditions such as abnormal baseline laboratory results. All these criteria need careful evaluation and discussion
not only within the research team and the sponsor of the trial, but also with the ethics committees, the regulatory
agencies overseeing the trial, and the communities in which the trial will take place, to assure that the trial results can
be generalized to the intended population. It is common practice to exclude persons who are very sick from a trial
(unless, of course, the trial intervention is directed at such persons). This is done because early deaths, or other SAEs
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in such persons, may occur independently of the trial intervention but may complicate interpretation of the effects of
the intervention.
Signing a written informed consent form is now a standard inclusion criterion in most clinical trials (see Chapter 6).
However, such a requirement will select a subgroup of the population who accept to sign such a form and participate
in the study, generating a potential selection bias. To measure how strong that bias may be, it is important to register
all eligible subjects who were considered as potential participants in the trial, indicating the reasons for refusal for
those who did not enter into the trial.
2.3. Death and verbal autopsies
Preventing deaths (or severe disabilities) is one of the most important public health outcomes of any type of treatment
or preventive intervention. It is the most important outcome in driving disease control policies and the introduction of
new interventions or treatments into the population, once they have been found to be safe and effective. These types
of outcomes have the heaviest weight in terms of disability-adjusted life-years (DALYs), when undertaking cost-
effectiveness analyses of new drugs or interventions (see Chapter 19). Therefore, trials designed to evaluate these
outcomes are very important. But, for many reasons, they may be difficult and costly to conduct, and, in many cases,
they may not be feasible or ethical to do. Counting deaths in the conduct of a trial is a very sensitive issue, particularly
in developing countries with poor health systems. It may create moral issues or generate political tension that may
stop the trial. Therefore, few trials are done with these important outcomes, despite their major importance. However,
those trials that are done with this endpoint and which demonstrate that an intervention significantly reduces mortality
are most likely to influence a policy decision on a more widespread introduction of the intervention.
When deaths or severe disability are chosen as study outcomes, several problems emerge, depending on the setting
where the study is conducted. In many LMICs, the quality of vital registration systems is poor or they are non-
existent, precluding their use. Therefore, methods are needed to identify deaths, as well as to establish causes of death.
In LMICs, the most commonly used method to ascertain causes of death are ‘verbal autopsies’. A verbal autopsy is a
structured interview, conducted with the relatives of the deceased person, with the intention to reconstruct the series of
events that led to the death (or severe complication or disability). Standard verbal autopsy questionnaires have been
developed (World Health Organization, 2012). Such ‘autopsies’ should be conducted neither too soon after the death
(to avoid asking questions when relatives are still very upset by the death) nor too long after the death (to avoid recall
bias). This interview is then analysed in a standardized way, either by physicians or using a computer algorithm, to
classify the likely cause of the death, following a predefined set of criteria (Lopez et al., 2011).
The reliability of verbal autopsy methods varies according to the cause of death, as some causes of death may be
confused because signs and symptoms in the illness leading up to death may be similar. The usefulness of verbal
autopsies is also dependent on the culture of the population under surveillance. It is essential to pilot-test the
(translated) questionnaire to assure that appropriate local words are used to ascertain signs or symptoms of the causes
of death.
In many populations, there could be a wide range of reasons why deaths may not be reported, and therefore special
care should be taken to ensure that ascertainment is as complete as possible. This becomes crucial when the study
outcome is death in the perinatal period, since an important proportion of live births that die in the minutes or hours
after birth could be either missed or wrongly reported as stillbirths. In some trials, members of the study community
may be hired as local informants to report any deaths. Other techniques include enumerating all members in a
community and checking for the absence of any of them in frequently conducted cross-sectional surveys. Special
attention should be paid to households for which all members are absent during one of these follow-up surveys,
because the death of an adult may lead to dissolution of a household or migration of household members. Enquiries
should be made with neighbours in such circumstances. Training and standardization of interviewers are essential.
The frequency of surveillance will be a critical decision in designing trials with mortality outcomes, since a long
recall period (such as 1 year) may miss deaths, particularly of children or infants; but each additional surveillance
round will be expensive.
2.4. Non-clinical case definitions
Non-clinical case definitions can also be used in trials such as quality of life in trials of the use of chemotherapy for
advanced cancer, antibiotic use in children in settings where they are available without prescription, satisfaction of
users of a health service, and economic outcomes (costs) which are discussed in Chapter 19. They also may include
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◆
outcomes that come directly from patients about how they feel or function in relation to a health condition and its
therapy (so called patient-reported outcomes), without interpretation by health care professionals or anyone else. For
these case definitions, instruments that have been developed previously or that are created especially for the trial need
to be validated, in order to have valid and comparable results.
2.5. Proxy measurements as study outcomes
Some trials may select outcome measures that are associated with the outcome of interest such as reported risky
sexual behaviour, which are either easier to measure, cheaper, or more socially acceptable. Those outcomes are called
‘proxy’ measurements of the outcome of interest. Such measures, however, may be subject to invalidity and bias (for
example, misreporting, differential degrees of desirability bias between trial arms).
2.5.1. Behavioural changes
A behaviour thought to be critical to reduce the disease of interest might be selected as a study outcome. For example,
in a study to investigate the effectiveness of a health education campaign to promote the use of latrines, where the
ultimate objective was to reduce diarrhoeal disease, the frequency of use of latrines might be measured. Sometimes,
health-related behaviours may be measured by direct observation.
Changes in knowledge or attitudes are sometimes an important initial step before a behaviour is changed, which, once
changed, should reduce the risk of the disease of interest. Knowledge or attitudes can be assessed with reasonable
reliability, using questionnaires or other interview methods, but observational studies may be required to determine if
behavioural changes have actually occurred. For example, in a study to investigate the effectiveness of a health
education campaign to promote the use of latrines, it may be relatively straightforward to assess, after the campaign,
whether individuals have a better knowledge of why using latrines is desirable, but observational studies, before and
after the campaign, may be necessary to ascertain whether or not the frequency of use of latrines had actually
changed, let alone whether behavioural change led to a reduction in the incidence of diarrhoea. Similar issues arise
with respect to the evaluation of a hand-washing intervention campaign. Further studies may then be needed to
determine whether the changed behaviour has led to a reduction of diarrhoeal diseases.
Some trials have the incidence of a self-reported behaviour as one of their outcomes. For example, in evaluating the
effectiveness of sexual behaviour change interventions, it is not possible to observe sexual behaviours directly, so self-
reported behaviours are frequently recorded. But such measures are very open to desirability bias where the
respondent reports the behaviour that they think the investigator would judge to be the desirable one. Furthermore, the
desirability bias may be differential between the trial arms. For example, if the intervention group has been
encouraged to reduce their number of sexual partners and always use a condom, while the control group has not, the
intervention group may be more likely to over-report these ‘desired’ behaviours at follow-up. Self-reported
behaviours, though sometimes the only practical outcome for a trial, are potentially misleading and should be avoided,
at least as the primary outcome measure in a trial, if at all possible.
2.5.2. Transmission reduction
The purpose of interventions, based on vector control or environmental alteration, may be to reduce or interrupt
transmission of the infectious agent of interest. Generally, the first priority is to determine whether the intervention
has accomplished the immediate changes intended. For example, in trials in which insecticides are applied to reduce
vector populations in order to reduce the transmission of some infectious agent, the first step would be to determine
the impact of the intervention on the vector population. If the vector population is little affected, it may be reasonable
to conclude that any impact on human disease is unlikely. However, if there is a reduction in vector population, it may
be erroneous to conclude that the human disease load will also fall. A further study to determine the impact on disease
may be required. Similarly, if interventions are being evaluated that may reduce indoor air pollution as a measure
against respiratory disease, it may be best to focus initial studies on the assessment of changes in pollution levels,
before assessing the impact on respiratory diseases. Usually, it will be more efficient to carry out trials to monitor the
impact on disease only after there is evidence of an effect on the vector or on the agent against which the intervention
is directed.
In order to assess a change in transmission, any, or all, of several different outcomes may be used:
incidence of infection or disease






prevalence of infection or disease
severity of disease
intensity of infection (for example, for helminths)
intensity of infective agent in the vector.
Any changes to these different outcomes will happen at different intervals after the intervention is in place, and may
require studies over time to measure the overall study impact. For instance, in an onchocerciasis control programme,
the first evidence that an intensive larviciding of Simulium damnosum (black fly) breeding sites is having an effect
may be a dramatic drop in fly-biting rates in the intervention area. Over the next several years, there may be a steady
fall in the intensity of microfilarial infections among those living in the endemic area, but only after some years might
it be possible to detect evidence of a fall in the prevalence of infection, and later still an impact on blindness rates
which is the major adverse health consequence of onchocercal infection.
2.6. Adverse events
An important outcome of all trials is to assess the safety of the intervention under evaluation (for example, of a new
drug or vaccine). Adverse events (AEs) are defined as any untoward clinical or laboratorial medical occurrence in a
patient or clinical investigation subject, related or not to the use of an intervention in a trial. Serious AEs (SAEs) are
defined as any events that are life-threatening or result in death. They include patient hospitalization or prolongation
of existing hospitalization, events that result in persistent or significant debilitation or incapacity, and congenital
anomalies and birth defects. All SAEs should be reported immediately to the sponsor (or the DSMB on behalf of the
sponsor), followed by detailed written reports (see Chapter 7). Usually, two types of study outcomes are defined: (1)
the active, prospective evaluation of a set of predefined potential AEs known or suspected to be associated with the
type of drug, vaccine, or product under evaluation, and (2) recording all clinical or laboratory abnormalities, expected
or not, that occur in study subjects during a specified time period or throughout the conduct of the trial, by active or
passive surveillance, which may reveal an adverse consequence previously not known to occur with the drug, vaccine,
or product under evaluation. For both types of safety outcomes, criteria must be developed to assess the severity, as
well as the incidence of AEs associated with the drug, vaccine, or product under evaluation. Severity can be measured
by the magnitude of a laboratory or clinical test abnormality, or by the subjective perception on how much the AE
altered the function or quality of life of the individual. For instance, a reaction at the site of injection of a vaccine
could be graded as mild if only a colour change is noted with mild pain, without induration and without any restriction
on the arm or leg movement; moderate if, in addition to colour change of the skin, induration is noted and there is
some restriction of movement; and severe if the subject cries out or winces if the area is touched and the arm or leg
cannot be moved without pain. In many studies, a diary card may be provided to the study subject or, in case of
children, to the mother or caretaker to record these reactions during a 7- or 14-day period after the administration of a
vaccine or during the drug therapy. To aid measuring an injection site reaction, a ruler may be provided to the subject.
And to standardize the measurement of temperature, a digital thermometer may be provided as well. Study subjects or
children’s mothers or caretakers need to be appropriately trained in using these study cards and instruments. In
addition to its severity, these reactions are usually classified as unrelated, unlikely to be related, or possibly related to
the intervention under evaluation. The criteria used for this classification may include proximity of the event to the
administration of the intervention (for instance, a rash developing within 20 minutes of an injection would most likely
be classified as possibly related), the unusualness of the clinical event (a disease which normally occurs in that age
group or a complication expected to happen in the disease under study), or even the subjective interpretation of the
investigator. Whatever criteria are used should be stated. The incidences of AEs, graded by the severity and likelihood
of being related to the interventional product, are later compared between the study group exposed to the intervention
and the control group (using placebo or an active comparator) to assess statistically if AEs of different kinds were or
were not associated with the drug, vaccine, or product.
All safety measurements need careful definition in the study protocol, study forms to record them, using standardized
measurements and codes to register them, and active monitoring of their occurrence. Most trials require those AEs
that are considered serious to be individually reported to the sponsor and to an ethics review board, to the regulatory
agency overseeing the trial, and to an independent DSMB for their careful evaluation during the conduct of the trial,
to allow the possibility for the trial to be stopped or modified before its completion if it is suspected that SAEs are
associated with the drug, vaccine, or product under investigation.
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3. Factors influencing choice of outcome measures
The choice of the outcome measures in a specific trial largely depends on the purpose of the trial and how relevant,
feasible, and acceptable the measures will be in a particular study population. Furthermore, the choice may be
constrained by economic, logistic, or ethical considerations.
3.1. Relevance
Interventions are generally designed to reduce disease and/or to promote health. The outcome measures chosen should
reflect these objectives as fully as possible, but, when intermediate variables are used, rather than those of main
interest, care must be taken to choose variables of direct relevance to the main outcome. This is not always
straightforward. For example, it may be decided to assess the impact of a vaccine by measuring the proportion of
individuals who develop antibodies to the vaccine. This may be reasonable if it is known that there is a high
correlation between the development of antibodies and protection from clinical disease. For many diseases, however,
this relationship has not been established, and it would not be warranted to base conclusions regarding protection
against disease simply on antibody determinations.
A health education intervention may be designed to change behaviour to reduce disease risk, but, as discussed in
Section 2.5.1, asking individuals if they have changed their behaviour may give a measure of impact that correlates
poorly with true changes in the risk of disease. Are individuals responding truthfully? Are they doing what they say
they do? Even if behaviour changes, is this associated with a lowering in the incidence of disease?
The outcome variable measured should be as close as possible to the outcome of main interest. While this may seem
an obvious suggestion, it may have major impact on the design of a study. For example, if the prevention of death is
of prime interest, then, whenever possible, this should be made the endpoint of the trial. To do so might require an
increase in the size of the trial from hundreds to thousands, or even tens of thousands, of individuals. Such a large trial
might be difficult to find funding for, and there may never be an adequate test of whether the intermediate variables
measured are acceptable surrogates for effects on mortality.
3.2. Feasibility
To be successful, a trial must be designed to have achievable objectives. A trial which has mortality as the endpoint,
but which is too large to be successfully completed, may be of less value than a well-designed smaller trial aimed at
assessing the impact on some intermediate endpoint such as severe disease. There must often be a compromise
between relevance and feasibility. It is pointless to set unachievable goals, even if they look attractive in the objectives
section of a proposal. Also, it may be of little value to measure the effect of an intervention on an outcome measure
which is only distantly related to the measure of prime interest. The outcome measures selected will be much
influenced by the resources available for the trial, the availability of skilled personnel, and the necessary laboratory
support to diagnose cases of disease. In many large trials, every individual in the study population may have to be
screened for disease or infection in a relatively short time. With such time constraints, some individuals may be
misdiagnosed. The consequences of reductions in diagnostic sensitivity and specificity are discussed in Section 4.2.
3.3. Acceptability
The acceptability of the measurement of an outcome variable to the study population is critical to the successful
conduct of a trial. For example, the recording of birthweights may not be possible in a population that allows only
close relatives to have access to a mother for a few days or weeks after the child’s birth. Taking venous blood samples
or repeated blood samples is unpopular in many societies. If the method for measuring the outcome involves pain or
inconvenience to the participants, it may be necessary to modify or abandon it. An outcome, of which the assessment
involves a long interview with participants at a time when they would otherwise be planting crops or taking care of
their household chores, may be unacceptable; it may either have to be abbreviated or carried out at a more convenient
time.
3.4. Opportunity for add-on studies
Some trials offer the opportunity to measure outcomes that are not directly related to the objectives of the original
study itself. These opportunities can be exploited by researchers to answer questions with minimal additional funding.
For example, a diarrhoeal surveillance study might be carried out within a clinical trial in which a cohort of healthy
children is being followed over time. However, it is very important that the add-on study does not interfere with the
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original study outcome measure. Such additions should be considered at the beginning of the study and should have a
separate study protocol. It is also important to inform sponsors, participants, and all stakeholders of the original trial
of the coexistence of the proposed add-on study. Such investigations will usually require separate ethical approval and
informed consent.
4. Variability and quality control of outcome measures
4.1. Reproducibility
The extent to which different observers will make the same diagnoses or assessments on a participant and to which
observers are consistent in their classifications between participants may have an important influence on the results of
a trial. Clearly, it is desirable to choose outcome measures for which there is substantial reproducibility and agreement
among observers, with respect to the classification of participants in the trial.
For objective outcome measures, variations between observers, or by the same observer at different times, may be
small and unlikely to influence the results of a study. For outcome measures requiring some degree of subjective
assessment, however, such variations may be substantial. The likely degree of such variations will influence the
choice of outcome measures, as it will be preferable to select those measures that have the smallest inter- and intra-
observer variations, yet still give valid measures of the impact of the intervention.
Variation among observers is often much greater than expected, for example, in the reading of a chest X-ray to assess
whether there is evidence of pneumonia. If a study involves several observers, pilot studies should be conducted, in
order to measure the extent of the variation and then to seek to standardize the assessment methods to minimize the
variation. With suitable training, it is usually possible to reduce the variation between observers substantially.
For some outcomes, independent assessment by two observers should be routine, with a third being called in to
resolve disagreements. It may be costly to screen the whole trial population in this way, but a common approach is to
have all suspected cases of the disease of interest examined by a second observer, mixed in with a sample of those not
thought to have the disease. Sometimes, it is possible to have the observer examine the same individual twice, but
these examinations may not be independent, unless the survey is large and the observer does not remember the result
of the first assessment.
It is important to make every effort to reduce variability to the maximum extent possible. Having done so, however, it
is also critical to know the extent of the remaining ‘irreducible’ variability for purposes of analysis. The purpose of
trials is usually to demonstrate the effect of an intervention or to compare differences between interventions.
Knowledge of the inherent variability in diagnostic procedures is essential for this demonstration, and the best way of
assessing this is through replicate measures. It is especially important to take account of between-observer differences
when communities are the units of randomization in a field trial. Differences between observers may produce biases if
different observers are used in different communities. In such situations, it is better to organize the fieldwork so that
the workload within each community is split among different observers and differences between the observers are not
confounded with the effect of the intervention.
4.2. Sensitivity and specificity
The choice of an appropriate definition of a ‘case’ in a field trial will be influenced by the sensitivity and specificity
associated with the diagnostic criteria. Sensitivity is defined as the proportion of true cases that are classified as cases
in the study. Specificity is the proportion of non-cases that are classified as non-cases in the study. A low sensitivity is
associated with a reduction in the measured incidence of the disease. This decreases the likelihood of observing a
significant difference between two groups in a trial of a given size. In statistical terms, it reduces the power of the
study (see Chapter 5, Section 2.2). If the incidence of the disease in both the intervention group and the comparison
group will be affected proportionately in the same way, as is often the case, it does not bias the estimate of the relative
disease incidence in the two groups, though the absolute magnitude of the difference will be less than the true
difference. Thus, in the context of a vaccine trial, because protective efficacy is assessed, in terms of relative
differences in incidence between groups, the estimate of protective efficacy will not be biased, but the confidence
limits on the estimate will be wider than they would be using a more sensitive case definition. In theory, the reduction
in power associated with low sensitivity can be compensated for by increasing the trial size.
In general, a low specificity of diagnosis is a more serious problem than a low sensitivity in intervention trials. A low
specificity results in the disease incidence rates being estimated to be higher than they really are, as some participants
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without the disease under study are classified incorrectly as cases. Generally, the levels of inflation in the rates will be
similar, in absolute terms, in the intervention and comparison groups, and thus the ratio of the measured rates in the
two groups will be less than the true ratio, though the difference in the rates should be unbiased. Thus, in vaccine
trials, for example, the vaccine efficacy estimate will be biased towards zero, though the absolute difference in the
rates between the intervention and control groups will not be biased (unless there is also poor sensitivity). Increasing
the trial size will not compensate for the bias in the estimate of vaccine efficacy.
In algebraic terms, suppose the true disease rates are  and  in the two groups under study, the true relative rate R is
, and the true difference in disease rates D is . If sensitivity is less than 100% (but specificity is 100%),
and only a proportion k of all cases are correctly diagnosed, the measured disease rates in the two groups will be 
and ; the measured relative rate will be ; and the measured difference in disease rates will be 
 (which will be less than D). If specificity is less than 100% (but sensitivity is 100%),
and the rate of false diagnoses is s, the measured rates in the two groups will be  and ; the measured
relative rate will be  (which will be less than R); and the measured difference in disease rates will be 
.
To measure the sensitivity and specificity of the diagnostic procedures used in a trial, it is necessary to have a ‘gold
standard’ for diagnosis (i.e. it is necessary to have a diagnostic procedure that determines who really is a case and
who is not). Sometimes, this is not possible, and, even if definitive diagnostic procedures exist, it may be necessary to
use imperfect procedures in a field trial for reasons of cost or logistics. In this situation, if an assessment is made of
sensitivity and specificity, it is possible to evaluate the consequences for the results of a field trial, and possible even
to correct for biases in efficacy estimates due to the use of a non-specific diagnostic test. Unfortunately, in many
situations, there is no ‘gold standard’, and so the sensitivity and specificity of the diagnostic methods used remain
uncertain. For example, there is no universally agreed definition of a case of clinical malaria. Most would agree that
the presence of parasites in the blood is necessary (unless a potential case has taken treatment before presenting to the
study clinic), and many would agree that the presence of fever associated with parasitaemia increases the likelihood of
the disease being clinical malaria, but it is also possible that the fever is due to other causes, rather than the
parasitaemia being the cause of the fever.
The bias induced by a low specificity of diagnosis is most severe for diseases that have a low incidence. A good
example of this is provided by leprosy, which is both difficult to diagnose (in the early stages) and also of low
incidence. Consider a vaccine trial in which the true disease incidence in the unvaccinated group is ten per thousand
over the period of the trial, and the true efficacy of a new vaccine against leprosy is 50%, i.e. the true disease
incidence in the vaccinated is five per thousand over the period of the trial. If the sensitivity of the diagnostic test used
for cases is 90%, but the specificity is 100%, the observed disease incidences would be 10 × 0.9 = 9.0 and 5 × 0.9 =
4.5 per thousand, respectively. Thus, the estimate of vaccine efficacy is correct (50%). The power of the study is
reduced, however. To achieve the power that would be associated with a ‘perfect’ test, the trial size would have to be
increased by about 11%.
On the other hand, if the specificity of the diagnostic test is as high as 99% and the sensitivity is 100%, the observed
disease incidences would be ten true cases + (990 × 0.01 = 9.9) false cases = 19.9 per thousand in the unvaccinated
group, and five true cases + (995 × 0.01 = 9.95) = 14.95 per thousand in the vaccinated group. Thus, even with a test
with 99% specificity, the estimate of vaccine efficacy is reduced from the true value of 50% to 25%. If the specificity
of the test were 90%, the expected estimate of vaccine efficacy would be only 4%.
In vaccine trials, the sensitivity and specificity of the diagnostic test are of consequence in different ways at different
times in the trial. When individuals are screened for entry to the trial, it is important that the test used should be highly
sensitive, even if it is not very specific, as substantial bias may be introduced if undiagnosed ‘cases’ are included in
the trial and included in the vaccinated or unvaccinated groups. If the vaccine has no effect on the progression of their
disease and they are detected as cases later in the trial, a false low estimate of efficacy will result. Thus, individuals
whose diagnosis is ‘doubtful’ at entry to the trial should be excluded from the trial. Conversely, once individuals have
been screened for entry into the trial and they are being followed for the development of disease, a highly specific test
is required to avoid the bias illustrated in the preceding paragraph.
In situations where there may be no clear-cut definitions of a case (for example, early leprosy or childhood TB),
studies of intra- and inter-observer variation may be undertaken, using various definitions of the disease. The
definition that shows the least disagreement between observers and gives maximum consistency within each observer
r1 r2
−r1 r2 /r1 r2
kr1
kr2 k /(k ) = Rr1 r2
k − k = k( − ) = kDr1 r2 r1 r2
( + s)r1 ( + s)r2
( + s)/( + s)r1 r2
( + s) − ( + s) = Dr1 r2
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may be the appropriate one to use in a trial, but the investigator should be aware of the potential for bias if the
specificity of the diagnostic procedure is less than 100%.
4.3. Bias
The most powerful way to minimize bias in the assessment of the impact of an intervention is through the conduct of
a double-blind randomized trial. If these two aspects are built into a trial, an effect of an intervention is not likely to be
observed if there is no true effect. However, as pointed out in Section 4.2, if the specificity of the diagnosis for the
outcome of interest is poor, the estimate of the efficacy of an intervention, measured in relative terms, may be biased
towards zero, even in a properly randomized double-blind investigation.
It is highly desirable that the person making diagnoses in a trial is ignorant of which intervention the suspected cases
have received. If the diagnosis is based on laboratory tests or X-ray examinations, blindness should be easy to
preserve. In some circumstances, it may be possible to determine from the results of a laboratory test which
intervention an individual has received, as the test may be measuring some intermediate effect between the
intervention and the outcome of prime interest (for example, an antibody response to a vaccine). In such cases, those
making diagnoses in the field should not be given access to the laboratory results. For example, in placebo-controlled
studies of praziquantel against schistosomiasis in communities where the infection is common, those who had
received the active drug would be easily detected by a rapid reduction in egg counts in stool or urine samples
following treatment. If the outcome of main interest is morbidity from the disease, then the egg count information
should be kept from those making the assessment of morbidity. It would generally be inappropriate to use measures of
antibody level to make diagnoses of disease following vaccination, if the vaccination itself induced antibodies
indistinguishable from those being measured. Similarly, tuberculin testing should not be part of diagnostic procedures
for TB in studies of the efficacy of BCG vaccination, as the vaccine alters the response to the test.
If the diagnosis of disease is based on a clinical examination, it may be necessary to take special precautions to
preserve blindness. An example is given in Chapter 11, Section 4, with respect to a BCG trial against leprosy, in
which all participants had the upper arm area, where BCG or placebo was injected, covered during the clinical
examination, since BCG leads to a permanent scar. Even if the participants know which intervention they had, it is
important to try to keep this knowledge from the person making any diagnoses. Thus, participants might be instructed
not to discuss the intervention with the examiner, and the examiner would be similarly restricted. Such a procedure is
obviously not fail-safe, but great efforts should be made to preserve blindness, if at all possible, especially if the
diagnosis is made on subjective criteria.
If randomization in a trial is by community, rather than by individuals, it may be especially difficult to keep examiners
ignorant of the intervention an individual received. Sometimes, ways can be found of doing this, for example, by
conducting surveys for disease by bringing all participants to a clinic outside the trial communities. If communities
are randomized to receive an improved water supply or not, one outcome measure of interest might be the incidence
of scabies infection. It may be difficult to avoid the possibility of the diagnoses of scabies being influenced by the
observer’s knowledge of whether or not the participant was in a village with an improved water supply. In such a case,
it may be best to seek other measures of impact, based upon objective criteria or laboratory measures, or to take
photographs of the relevant body parts and have these assessed objectively and ‘blind’ to intervention group.
4.4. The Hawthorne effect
Trials that require active home visits by study personnel during the surveillance period to evaluate the effect of an
intervention may be affected by an indirect effect of the home visits on the study objective, even when not intended.
The presence of a study member in a subject’s home may have a positive effect on the health status of the subject,
since it may, for example, stimulate better health behaviour of the subject or improve hygiene practices in the house or
better health care utilization. In studies with such effects, rates of illnesses or of severe illness may be reduced in both
study arms—an indirect effect known as the ‘Hawthorne effect’ (named after a study in the 1930s in the USA at the
Hawthorne Works, in which it was documented that worker behaviour changed as a consequence of them being
observed). This effect reduces the power of the study and may make it inconclusive. There is no easy way to control
for it, so, if such a Hawthorne effect is expected in a field trial, the sample size may need to be increased to maintain
statistical power.
4.5. Quality control issues
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The sensitivity and specificity of the diagnostic procedures employed in a trial should be monitored for the duration of
the trial, as they may change as the study progresses. Such changes may be for the worse or for the better. With
experience, diagnostic skills may improve, but also, as time passes, the staff may become bored and take less care. It
is important that the field staff are aware that their performance is being continuously monitored. If this is done, then
anyone who goes ‘off the rails’ can be steered back or removed from the study, before much harm is done. Such
monitoring is important for both field and laboratory staff.
The methods used to monitor the quality of diagnostic procedures may include the re-examination of a sample of
cases by a supervisor or a more highly trained investigator and, for the laboratory, may be done by sending a sample
of specimens to a reference laboratory and by passing some specimens through the laboratory in duplicate, in a
blinded fashion, to determine if the differences between results on the same specimen are within acceptable limits (see
Chapter 17, Section 5).
If the disease under study is relatively rare, it may be difficult to measure sensitivity based on small numbers of
individuals being examined twice. While it will be possible to check if specificity is poor (a high proportion of those
classified as cases are wrongly diagnosed), checks on sensitivity may involve the examination of thousands of
individuals twice to determine if cases are being missed. Fortunately, in most trials, specificity is of more critical
importance than sensitivity, although the relative importance can change as the survey goes on, as discussed in
Section 4.2.
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The main purpose of the trial was to evaluate the public health
impact of the vaccine. First episodes of radiological pneumonia
were reduced by 37% (and all-cause mortality by 16%—not a
primary endpoint in the trial). Highest efficacy was expected
against invasive pneumococcal disease due to serotypes in the
vaccine, but the aetiology of most cases of pneumonia is difficult
to establish.


























































The intervention was designed to reduce HIV incidence through
behaviour change brought about by sexual health education. A
substantial number of secondary outcomes were included to
facilitate understanding of the main results. This was important,
as the intervention was shown to substantially improve
knowledge, reported attitudes, and some reported sexual


























This was a test of a new approach to malaria control by
administering anti-malarial drugs routinely to infants attending
clinics for vaccination. Clinical malaria was reduced by 59%,
and severe anaemia by 50%
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